LP
NVAX icon

LMR Partners’s Novavax NVAX Stock Holding History

LMR Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,800
Closed -$427K – 1482
2024
Q3 		$427K Sell
33,800
-50,000
-60% -$646K ﹤0.01% 859
2024
Q2 		$1.06M Buy
+83,800
New +$843K 0.01% 666
2024
Q1 		– Sell
-30,000
Closed -$144K – 1264
2023
Q4 		$144K Sell
30,000
-92,400
-75% -$566K ﹤0.01% 748
2023
Q3 		$886K Buy
+122,400
New +$978K 0.01% 503

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's NVAX Position: Q1 2025 in Review

LMR Partners sold out of Novavax (NVAX) in Q1 2025, closing a stake of 31,613 shares — an estimated $254K sold.

LMR Partners first reported a position in NVAX in Q4 2020 and held it in 8 quarters. The position peaked at $33.2M in Q4 2021. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • LMR Partners reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 31,613 Novavax shares in Q1 2025, an estimated $254K.
  • LMR Partners first reported a position in Novavax in Q4 2020 and held it in 8 quarters.
  • LMR Partners's Novavax position peaked at $33.2M in Q4 2021.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.